Table 2 Tumor characteristics and type of treatment
Variables | Group | |||
|---|---|---|---|---|
GHipo (n = 23) | GConv (n = 43) | Total (n = 66) | p-value | |
Primary tumor | n (%) | n (%) | n (%) | |
Oral cavity | 12 (52.2%) | 16 (37.2%) | 28 (42.4%) | 0.779# |
Pharynx | 7 (30,4%) | 16 (37.2%) | 23 (34.8%) | |
Salivary gland | 2 (8.7%) | 3 (7.0%) | 4 (7.6%) | |
Larynx | 1 (4.3%) | 5 (11.6%) | 6 (9,1%) | |
Maxillary sinus | 1 (4.3%) | 3 (7.0%) | 4 (6.1%) | |
Clinical stagea | ||||
Early (0, I, II) | 2 (8.7%) | 8 (18.6%) | 10 (15.1%) | 0.465# # |
Advanced (III and IV) | 21 (91.3%) | 34 (79.1%) | 55 (25.8%) | |
Concomitant chemotherapy | ||||
No | 9 (39.1%) | 20 (46.5%) | 29 (43.9%) | 0.611# # |
Yes | 14 (60.9%) | 23 (53.5%) | 37 (56.1%) | |
Radiotherapy sessions Median (Min–Max) | 20 (20–20) | 35 (29—35) | ||